INS and diabetes mellitus: The clinical benefit of this immunomodulatory agent is the lack of severe adverse effects at a dose of 1 mg/kg body weight as applied in diabetes prevention studies in rodent models, including the LEW.1AR1-iddm (iddm) [65].